A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

Trial Profile

A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Apr 2018

At a glance

  • Drugs Perampanel (Primary)
  • Indications Partial epilepsies
  • Focus Registrational; Therapeutic Use
  • Acronyms EXPLORE-305
  • Sponsors Eisai Inc
  • Most Recent Events

    • 27 Apr 2018 Results (n=175) of post hoc multivariate analysis assessing clinical factors associated with a major response in phase III trials of adjunctive Perampanel in patients with partial seizures (Studies 304, 305 and 306), presented at the 70th Annual Meeting of the American Academy of Neurology.
    • 27 Apr 2018 Results (n=1480) assessing perampanel as monotherapy for partial seizures by extrapolating adjunctive efficacy and safety data from phase III trials (EXPLORE-304, EXPLORE-305 and EXPLORE-306), presented at the 70th Annual Meeting of the American Academy of Neurology.
    • 05 Dec 2017 Results of post hoc analysis of open label extension studies, presented at the 71st Annual Meeting of the American Epilepsy Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top